main image

Association of International
Research- based Pharmaceuticals

The main basic kinds of operations of the Association are:

To promote cooperation among the Association members
To represent the interests of its members in relations with state institutions and other companies
To inform about the pressing issues and news in the pharmaceutical market
To support development of a pharmaceutical market environment in Latvia meeting the international requirements

About us

Association of International Research-based Pharmaceuticals Manufacturers (SIFFA) is an open voluntary public organisation. The goal of SIFFA is to promote the operations of pharmaceutical companies in Latvia, to improve the healthcare quality, to increase the level of education and expertise of physicians, chemists and general public, as well as to promote and support the organised pharmaceutical market development in cooperation with governmental authorities.

The objectives of SIFFA are to recommend its members the optimal solution of their problems, to respond adequately to any situation whenever any person’s actions infringe on the rights and legitimate interests of an SIFFA member, to use the whole range of possibilities to solve the existing problems.

SIFFA was founded in January 1996 and initially united five representatives of foreign pharmaceutical firms operating in Latvia (Glaxo Welcome, Merck Sharp & Dohme, Boehringer Ingelheim, Schering and Eli Lilly). At the present, SIFFA unites 19 members, representing: AbbVie, AstraZeneca, Bayer, Berlin–Chemie/Menarini, Boeringer Ingelheim, Biogen, Eli Lilly, Gedeon Richter, Ipsen, Johnson & Johnson, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, Santen, Servier International, Takeda.

SIFFA members are the world’s biggest manufacturers of pharmaceutical products, by their turnover and capitalisation also ranking among the world’s biggest companies in general. The Association members are engaged in both medicine production and development and research of new medicines.

Latest news

5. July, 2021
Par datu publiskošanu
6. May, 2021
SIFFA strongly supports the EFPIA statement on IP waiver for COVID-19 vaccines
6. April, 2021
Medikamenti ir pieejami, bet ne Latvijas pacientiem – valsts kompensējamo medikamentu budžeta deficīts uz pirmo martu ir 80,38 miljoni eiro
12. March, 2021
SIFFA aug un uzņem savā ģimenē kompāniju Amgen un Biogen
4. December, 2020
Spēkā stājies jaunais kodekss
2. December, 2020
Pusgada laikā kompensējamo zāļu saraksts Latvijā papildināts ar 3 inovatīviem medikamentiem